Major risks of dual and triple antithrombotic therapy in patients with newly diagnosed atrial fibrillation

March 5, 2013

According to Dr. Samy Suissa, Director of Clinical Epidemiology, Jewish General Hospital, and Professor of Epidemiology, McGill University in Montreal, Canada, "treating physicians need to consider the clinical effectiveness of combining different antithrombotic therapies against the likelihood of increasing the risk of serious bleeding." This new study, published in the March 2013 issue of Thrombosis and Haemostasis, quantified the risk of bleeding events associated with antithrombotic combination therapy in a large population-based cohort of patients newly diagnosed with atrial fibrillation. These findings suggest that while all antithrombotic therapies are associated with an elevated bleeding risk, chances are greatly increased in an additive manner with dual and triple therapy, particularly in combinations containing warfarin.

Patients with atrial fibrillation are at an increased risk of . In this high-risk population, vitamin K antagonists such as have been shown to be highly effective in preventing this event. However, the afflicted often receive multiple antithrombotic drugs such as warfarin in combination with aspirin and clopidogrel to manage their associated . Yet, each of these drugs is known to increase the bleeding risk, and especially intracranial hemorrhage. Moreover, intracranial hemorrhage associated with the use of warfarin is often fatal.

Nonetheless, very few population-based studies have explicitly quantified the risk associated with combined treatment to date.

Thus the primary purpose of this current research was to find out more about the association between the concurrent use of different antithrombotic drugs and the bleeding risk in patients newly diagnosed with atrial fibrillation, who seem to be at an even higher risk of bleeding than patients with chronic disease. Suissa and his team conducted a population-based cohort study, relying on the General Practice Research Database (GPRD), a primary care database from the United Kingdom, to identify patients newly diagnosed with atrial fibrillation between 1993 and 2008. Within this cohort including more than 70,000 adults (mean age: 74.1 years), 10,850 patients experienced a bleeding event during follow-up (604 of which were intracranial hemorrhages).

The risk of bleeding episodes with dual and triple antithrombotic therapy was found to be additive, and chances of bleeding events increased in particular with combinations containing warfarin. Triple therapy was associated with the highest risk: For the combined use of both aspirin and with warfarin, the bleeding risk was increased almost 4-fold compared with non-use. When compared with warfarin single therapy, triple therapy was associated with an 80% increased risk.

These results are clinically significant and might help to refine management of patients with who often have further conditions indicated for these drugs. In view of these findings, patients currently treated with multiple antithrombotic therapies in combination should discuss with their physician the risk-benefit profile of such combination treatment with respect to the potential additive bleeding risks.

Explore further: Apixaban superior to warfarin across range of patient risk scores

More information: Azoulay L , Dell'Aniello S, Simon T, Renoux C , Suissa S. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost 2013; 109: 431-439. …

Related Stories

Apixaban superior to warfarin across range of patient risk scores

October 1, 2012
A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, according to Duke University Medical ...

Chronic kidney disease increases stroke risk in A-fib

August 16, 2012
(HealthDay) -- Patients with atrial fibrillation who have chronic kidney disease are at higher risk of stroke or systemic thromboembolism and bleeding, according to a study published in the Aug. 16 issue of the New England ...

Rivaroxaban has less risk of brain bleeding in patients at high risk for stroke

February 2, 2012
For patients with a type of irregular heart beat called atrial fibrillation (AF), a new anti-clotting drug might be better at preventing clot-related strokes while minimizing the risk of causing a bleeding stroke. The research ...

New scorecard identifies patients at highest risk on blood thinners

August 4, 2011
A new and simple risk score may aid physicians in gauging the likelihood that a common drug will cause a hemorrhagic stroke or other major bleeding in patients with atrial fibrillation, potentially allowing wider but safer ...

Risk of hemorrhage from warfarin higher in clinical practice than clinical trials show

November 26, 2012
Rates of hemorrhage for older patients on warfarin therapy are much higher than rates reported in clinical trials, found a study published in CMAJ (Canadian Medical Association Journal).

Recommended for you

Mouse studies shed light on how protein controls heart failure

October 18, 2017
A new study on two specially bred strains of mice has illuminated how abnormal addition of the chemical phosphate to a specific heart muscle protein may sabotage the way the protein behaves in a cell, and may damage the way ...

Newborns with trisomy 13 or 18 benefit from heart surgery, study finds

October 18, 2017
Heart surgery significantly decreases in-hospital mortality among infants with either of two genetic disorders that cause severe physical and intellectual disabilities, according to a new study by a researcher at the Stanford ...

Saving hearts after heart attacks: Overexpression of a gene enhances repair of dead muscle

October 17, 2017
University of Alabama at Birmingham biomedical engineers report a significant advance in efforts to repair a damaged heart after a heart attack, using grafted heart-muscle cells to create a repair patch. The key was overexpressing ...

High blood pressure linked to common heart valve disorder

October 17, 2017
For the first time, a strong link has been established between high blood pressure and the most common heart valve disorder in high-income countries, by new research from The George Institute for Global Health at the University ...

Blood cancer gene could be key to preventing heart failure

October 16, 2017
A new study, published today in Circulation, shows that the gene Runx1 increases in damaged heart muscle after a heart attack. An international collaboration led by researchers from the University of Glasgow, found that mice ...

Mitochondrial DNA could predict risk for sudden cardiac death, heart disease

October 11, 2017
Johns Hopkins researchers report that the level, or "copy number," of mitochondrial DNA—genetic information stored not in a cell's nucleus but in the body's energy-creating mitochondria—is a novel and distinct biomarker ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.